HD-OPM Archive
Topics › LDL, ApoB & lipid panel

Mendelian randomization: higher ApoB shortens healthspan and may raise Alzheimer's risk

Gokhan Can · Feb 25, 2024 · ♥ 25 reactions · 4 comments · original Facebook post
LDL, ApoB & lipid panelBrain health & dementiaAging & longevity
AI summary & key facts

Summarizes Martin et al. 2024, a Mendelian randomization study finding that genetically higher ApoB shortens healthspan (time to first chronic disease), with a direct effect independent of LDL. ApoB, but not LDL, also appeared to raise Alzheimer's risk, though the replication attenuated in a larger sample.

Breaking news! Lower ApoB was found to be causatively associated with increased healthspan and reduced Alzheimer's disease risk. A more detailed summary down below.


Martin et al. (2024) performed a Mendelian randomization (MR) study to investigate whether circulating apolipoprotein B (APOB) and APOB-containing lipoproteins influence healthspan and risk for Alzheimer's disease (AD). Healthspan was defined as the time between birth and onset of chronic disease. Their main conclusions were:

  1. Higher levels of APOB and 8 APOB-containing lipoproteins containing low-density lipoprotein (LDL) particles shorten healthspan based on an MR screen of 103 nuclear magnetic resonance (NMR)-measured metabolites. Each 1 standard deviation increase in APOB levels shortened healthspan by 0.06 years (95% CI: -0.09, -0.03; P=7.56×10-6).
  2. Higher levels of APOB shorten healthspan based on MR analyses using larger genetic instruments from the UK Biobank. APOB levels explained 9% of variance in NMR-APOB levels. Each 1 SD increase in APOB shortened healthspan by 0.13 years (95% CI: -0.18, -0.09; P=1.38×10-9).
  3. Higher LDL levels shorten healthspan. LDL levels explained 8% of variance. Each 1 SD increase in LDL shortened healthspan by 0.12 years (95% CI: -0.15, -0.08; P=4.08×10-10).
  4. Multivariable MR analysis indicated APOB has a direct causal effect on shortening healthspan independent of LDL levels. When accounting for LDL, each 1 SD increase in APOB shortened healthspan by 0.25 years (95% CI: -0.41, -0.09; P=0.001).
  5. APOB, but not LDL, likely increases risk for AD based on MR analyses. Each 1 SD increase in APOB levels increased odds of AD by 28% (OR: 1.28; 95% CI: 1.13, 1.37; P=3.94×10-5).
  6. MR of APOB on AD partially replicated using 71,880 AD cases (vs 21,982 cases in main analysis), though the effect attenuated towards the null.
  7. Transcriptomic SMR analysis identified 2 genes whose expression in blood influences APOB levels: PELO and PYGB. These may be targets for therapies aiming to modify APOB.

The MR screen of 103 NMR metabolites revealed 9 hits that shortened healthspan after Bonferroni correction (adjusted P<4.85×10-4 for 103 tests): APOB and 8 LDL-related lipoproteins. The 8 LDL-related lipoproteins were: cholesterol in large LDL, cholesterol esters in large LDL, free cholesterol in large LDL, total lipids in large LDL, concentration of large LDL particles, phospholipids in large LDL, phospholipids in medium LDL, and total lipids in small very low-density lipoprotein.

The authors performed extensive sensitivity analyses to test core MR assumptions and check for pleiotropy, which could bias causal estimates. Sensitivity estimators (MR Egger, weighted median, weighted mode) aligned closely with the main inverse variance weighted (IVW) estimator for the MR tests, providing evidence against pleiotropy. MR Egger intercept tests also suggested no evidence of pleiotropy.

To further investigate the top findings for APOB and LDL, the authors performed MR tests using larger sample sizes from the UK Biobank (~440,000 people). They created genetic instruments containing 91 SNPs for APOB and 90 SNPs for LDL. The SNPs explained 2% and 3% of variance in APOB and LDL levels, respectively.

For APOB, the IVW estimator indicated each 1 SD higher level shortened healthspan by 0.13 years (95% CI: -0.18, -0.09; P=1.38×10-9). The sensitivity estimators closely aligned, consistent with a lack of pleiotropy: MR Egger -0.12 years (95% CI: -0.20, -0.05); weighted median -0.15 years (95% CI: -0.22, -0.07); weighted mode -0.14 years (95% CI: -0.22, -0.06).

For LDL, the IVW estimator indicated each 1 SD higher level shortened healthspan by 0.12 years (95% CI: -0.15, -0.08; P=4.08×10-10). The sensitivity estimators closely aligned: MR Egger -0.11 years (95% CI: -0.17, -0.05); weighted median -0.11 years (95% CI: -0.17, -0.06); weighted mode -0.12 years (95% CI: -0.18, -0.07).

The multivariable MR analysis revealed that while accounting for LDL levels, each 1 SD higher APOB level shortened healthspan by 0.25 years (95% CI: -0.41, -0.09; P=0.001). In contrast, while accounting for APOB levels, the effect of LDL on healthspan was null. This suggests APOB is more relevant to healthspan than LDL.

For AD risk, based on the IGAP cohort (21,982 cases; 41,944 controls), the IVW estimator indicated each 1 SD higher APOB level increased AD odds by 28% (OR: 1.28; 95% CI: 1.13, 1.37; P=3.94×10-5). The sensitivity estimators aligned closely. In contrast, the MR test for LDL on AD risk was null.

The partial replication MR test of APOB on AD using 71,880 cases (some proxy cases) from Jansen et al. (including IGAP participants) was directionally consistent but attenuated toward the null: IVW OR per 1 SD higher APOB = 1.02 (95% CI: 1.01, 1.04; P=1.44×10-3).

The transcriptomic SMR analysis identified 10 genes whose expression in blood influenced APOB levels after multiple testing correction. Bayesian colocalization provided evidence that 2 genes had a high posterior probability (PP4 > 0.80) of containing causal variants: PELO (PP4=0.94) and PYGB (PP4=1). These may be useful therapeutic targets.

In summary, Martin et al. used multiple MR methods and performed extensive sensitivity analyses to provide evidence that APOB likely directly and negatively impacts healthspan. They also found preliminary evidence that APOB may increase AD risk. If confirmed by future studies, these relationships suggest strategies targeting APOB could improve health with age.

Paper · Commun Biol · 2024Mendelian randomization reveals apolipoprotein B shortens healthspan and possibly increases risk for Alzheimer’s diseaseApolipoprotein B-100 (APOB) is a component of fat- and cholesterol-transporting molecules in the bloodstream. It is the main lipoprotein in low-density lipoprotein cholesterol (LDL) and has been implicated in conditions that end healthspan (the interval between birth and onset of chronic disease). However, APOB’s direct relationship with healthspan remains uncertain. With Mendelian randomization, we show that higher…nature.com

Research cited

#apob#healthspan#alzheimers#cholesterol#mendelianrandomization#genetics
← newer: Question about eating sushi and sashimi dailyolder: Video: Rhonda Patrick on the best exercise for abdominal fat →